摘要
目的探讨LMR值对R-CHOP方案初治滤泡性淋巴瘤患者的效果及预后的影响。方法选择2013年1月~2016年1月在我院诊断治疗的初始滤泡淋巴瘤患者88例为研究对象,所有患者均采用R-CHOP方案化疗。比较低危、中危、高危患者的临床疗效及预后;比较LMR≥4.7与<4.7患者临床疗效及预后。结果低危患者总有效率最高,其次为中危组,高危组最低,差异有统计学意义(P<0.05)。LMR≥4.7患者临床疗效显著高于<4.7组,差异有统计学意义(P<0.05)。低危患者平均生存期最长,其次为中危,两组均显著高于高危患者,差异有统计学意义(P<0.05);低危组3年无进展生存率显著高于高危组,第2年生存率与第3年生存率显著高于高危组,差异有统计学意义(P<0.05)。LMR≥4.7患者平均生存率显著较<4.7的患者,3年无进展生存率显著高于<4.7的患者,第2年生存率与第3年生存率均显著高于<4.7的患者,差异有统计学意义(P<0.05)。结论LMR≥4.7初治滤泡性淋巴瘤患者采用R-CHOP方案化疗效果更好,3年无进展生存率更高。
Objective To investigate the effect of LMR on the efficacy and prognosis of patients with newly diagnosed follicular lymphoma initially treated by R-CHOP regimen. Methods 88 patients with initial follicular lymphoma diagnosed and treated in our hospital from January 2013 to January 2016 were selected as subjects. All patients were treated with R-CHOP chemotherapy. The clinical efficacy and prognosis of low-risk, intermediate-risk, high-risk patients were compared. The clinical efficacy and prognosis of patients with LMR≥4.7 and <4.7 were compared. Results The low-risk patients had the highest total efficiency, followed by the intermediate-risk group, and the high-risk group was the lowest, and the difference was statistically significant(P<0.05). The clinical efficacy of patients with LMR≥4.7 group was significantly higher than that of the LMR <4.7 group, and the difference was statistically significant(P<0.05).The average survival time of the low-risk patients was the longest, followed by the intermediate risk, both significantly higher than that of the high-risk group. The difference was significant(P<0.05). The three-year progression-free survival rate in the low-risk group was significantly higher than that in the high-risk group. The 2-year survival rate and the 3rd year survival rate in the low- risk group were significantly higher than those of the high-risk group, and the difference was statistically significant (P<0.05). The average survival rate of patients with LMR ≥4.7 was significantly higher than that of patients with <4.7,and the three-year progression-free survival rate of patients with LMR ≥4.7 was significantly higher than that of patients with <4.7. The second-year survival rate and the third-year survival rate of patients with LMR ≥4.7 were significantly higher than those with<4.7, and the difference was statistically significant(P<0.05). Conclusion Patients with newly diagnosed follicular lymphoma with LMR ≥ 4.7 have better R-CHOP regimen and a higher 3-year progression-free survival rate.
作者
许能文
李琳洁
刘卫娥
陈延杰
朱梦萍
刘敏
周燕
XU Nengwen;LI Linjie;LIU Wei-e;CHEN Yanjie;ZHU Mengping;LIU Min;ZHOU Yan(Department of Hematology,Lishui Central Hospital in Zhejiang Province,Lishui 323000,China)
出处
《中国现代医生》
2019年第12期38-41,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2015KYB456)
关键词
R-CHOP化疗方案
初治滤泡性淋巴瘤
LMR值
预后
R-CHOP chemotherapy regimen
Initial treatment of follicular lymphoma
LMR value
Prognosis
